A novel series of [3.2.1] azabicyclic biaryl ethers as α3β4 and α6/4β4 nicotinic receptor agonists
摘要:
We report the synthesis of a series of [3.2.1]azabicyclic biaryl ethers as selective agonists of alpha 3- and alpha 6-containing nicotinic receptors. In particular, compound 17a from this series is a potent alpha 3 beta 4 and alpha 6/4 beta 4 receptor agonist in terms of both binding and functional activity. Compound 17a also shows potent in vivo activity in CNS-mediated animal models that are sensitive to antipsychotic drugs. Compound 17a may thus be a useful tool for studying the role of alpha 3 beta 4 and alpha 6/4 beta 4 nicotinic receptors in CNS pharmacology. (C) 2010 Elsevier Ltd. All rights reserved.
This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS
申请人:Hu Qi-Ying
公开号:US20120071514A1
公开(公告)日:2012-03-22
The present invention provides a compound of formula I;
a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Benzoxazolone derivatives as aldosterone synthase inhibitors
申请人:Hu Qi-Ying
公开号:US08455522B2
公开(公告)日:2013-06-04
The present invention provides a compound of formula I;
a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.